Skip to main content

Table 2 Numbers of patients positive on each ESSDAI domain and positive for moderate/high activity on each domain as a function of level of treatment with PSL

From: Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study

  Patients with positive activity level Patients with moderate/high activity level
All patients
(n = 31)
High/medium dose PSL
(n = 12)
No/low dose PSL
(n = 19)
High/medium dose PSL
(n = 12)
No/low dose PSL
(n = 12)
ESSDAI domain
 Constitutional 18 9 (50.0%) 9 (50.0%) 5 4
 Lymphadenopathy 9 3 (33.3%) 6 (66.7%) 1 0
 Glandular 10 5 (50.0%) 5 (50.0%) 4 0
 Articular 9 4 (44.4%) 5 (55.6%) 1 0
 Cutaneous 9 6 (66.7%) 3 (33.3%) 2 2
 Pulmonary 0 0 0 0 0
 Renal 1 1 (100%) 0 0 0
 Muscular 0 0 0 0 0
 PNS 2 2 (100%) 0 1 0
 CNS 3 3 (100%) 0 3 0
 Hematological 3 2 (66.7%) 1 (33.3%) 2 1
 Biological 18 10 (55.6%) 8 (44.4%) 9 7
  1. Abbreviations: ESSDAI EULAR Sjögren Syndrome Disease Activity Index, EULAR European League Against Rheumatism, PNS peripheral nervous system, CNS central nervous system, PSL prednisolone
  2. Glucocorticoid dosages were graded as high (prednisolone (PSL) ≥ 0.5 mg/kg/day or equivalent), medium (PSL ≥0.2 but < 0.5 mg/kg/day or equivalent) and low (PSL < 0.2 mg/kg/day or equivalent)